In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease
USP30 抑制剂在帕金森病相关模型中的体内评价
基本信息
- 批准号:10603217
- 负责人:
- 金额:$ 47.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAffectAgeAmericanAnimal ModelAnimalsAutomobile DrivingAutopsyBackBinding ProteinsBiochemicalBiological AssayBiological SciencesBiologyBiotechnologyBrainCell CountCell LineCellsCentral Nervous System DiseasesClinicClinicalClinical TrialsComplexCorpus striatum structureDataDeubiquitinating EnzymeDevelopmentDiseaseDisease PathwayDisease ProgressionDopamineDoseDrosophila genusDrug KineticsElementsExperimental DesignsFBXO7 geneFemaleFutureGeneticGenetic ModelsHomeostasisHumanHuman GeneticsIdiopathic Parkinson DiseaseIn VitroInvestigational DrugsInvestmentsKineticsKnowledgeLRRK2 geneLeadLettersLicensingLightLinkManuscriptsMeasuresMediatingMethodsMicrosomesMitochondriaModelingModificationMotorMusMutationNerve DegenerationNeurodegenerative DisordersNeuronal DifferentiationNeuronsOligomycinsOther GeneticsPINK1 genePaperParaquatParkinParkinson DiseasePathogenesisPathologyPathway interactionsPatientsPenetrationPermeabilityPersonsPharmaceutical ChemistryPharmacodynamicsPharmacologyPlasmaPlasma ProteinsPositioning AttributePropertyRattusRegimenRisk FactorsRodentSeriesSex DifferencesSolubilityStudy modelsSubstantia nigra structureTestingTherapeuticTissuesToxic effectToxinage relatedalpha synucleinantimycincell typeclinical developmentcytotoxicitydopaminergic neurondrug discoveryexperimental studyin vitro activityin vivoin vivo evaluationinduced pluripotent stem cellinhibitorknock-downlead candidatemalemitochondrial dysfunctionmouse modelmultidisciplinarynanomolarneuroprotectionneurotransmissionnoveloverexpressionpars compactapre-formed fibrilsmall moleculesmall molecule inhibitorsporadic Parkinson&aposs Diseasesuccessubiquitin isopeptidase
项目摘要
ABSTRACT
Existing treatments for Parkinson’s disease (PD), which affects 10 million people worldwide, primarily augment
dopaminergic neurotransmission to provide symptomatic benefit. No current therapy can slow or stop the
progression of PD. We propose a drug discovery platform to develop small molecules targeting the parkin-USP30
mitophagy pathway, which represents a key regulator of mitochondrial homeostasis. Converging lines of
evidence from human genetics, tissue pathology and biochemical studies from sporadic PD patients, and animal
model studies indicate that deficits in Mitophagy are a modifiable contributor to PD pathogenesis. Specifically,
inhibition or knockdown of the deubiquitinating enzyme USP30 can enhance mitophagy in a variety of cell types
and infers neuroprotection in two fruit fly models (pink1 deficiency and paraquat toxicity). However, studies
examining neurodegeneration in larger animals such as rodents are an unfilled gap in knowledge that should be
addressed prior to development of USP30 inhibitors as therapeutics for PD. In the proposed Aims, we will test
the hypothesis that USP30 inhibitor small molecules will protect against neurodegeneration induced by a
mitochondrial toxin MPTP, or a-synuclein preformed fibrils – both models with links to Parkinson’s disease and
mitophagy. Our preliminary data demonstrate that we have generated a series of small molecules that potently
and selectively inhibit USP30 activity in vitro, and demonstrate cellular activity without cytotoxicity in differentiated
neuronal cell lines. Top compounds have good in vitro ADME properties and a lead and back up compound have
been identified with excellent rat and mouse plasma and brain PK profiles which place us in a unique position to
examine the proposed hypothesis. If successful, the studies proposed in this application will justify further
investment toward development of our small molecules through Investigational New Drug filing (IND)-enabling
studies, out-license, or partnership with big pharma or biotech for further clinical development.
摘要
影响全球1000万人的帕金森病(PD)的现有治疗方法主要是增强
多巴胺能神经传递对症状有好处。目前没有一种治疗方法可以延缓或阻止
帕金森病的进展。我们提出了一个药物发现平台来开发针对Parkin-USP30的小分子
有丝分裂途径,它代表了线粒体动态平衡的关键调节因素。会聚的线条
来自散发性帕金森病患者和动物的人类遗传学、组织病理学和生化研究的证据
模型研究表明,吞丝分裂的缺陷是帕金森病发病的一个可修改的因素。具体来说,
抑制或敲除去泛素化酶USP30可以增强多种细胞的有丝分裂能力
并推断了两种果蝇模型(PINK1缺乏和百草枯中毒)的神经保护作用。然而,研究表明
研究啮齿动物等大型动物的神经退行性变是知识上的一个空白,本应
在开发USP30抑制剂作为帕金森病的治疗药物之前。在提议的目标中,我们将测试
假设USP30抑制剂小分子将保护由A诱导的神经变性
线粒体毒素MPTP,或a-突触核蛋白预制纤维-这两种模型都与帕金森病和
有丝分裂。我们的初步数据表明,我们已经产生了一系列有效的小分子
并在体外选择性地抑制USP30的活性,并在分化的细胞中表现出无细胞毒性的细胞活性
神经细胞系。TOP化合物具有良好的体外ADME性能,而先导和后备化合物具有
通过出色的大鼠和小鼠血浆和脑PK图谱进行鉴定,这使我们处于独特的位置
检验提出的假设。如果成功,本申请中提出的研究将进一步证明
通过启用研究性新药备案(IND)投资于我们的小分子开发
研究,获得许可,或与大型制药公司或生物技术公司合作进行进一步的临床开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bahareh Behrouz其他文献
Bahareh Behrouz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bahareh Behrouz', 18)}}的其他基金
Evaluation of USP30 small molecule inhibitors in models relevant to Cardiac Aging
USP30 小分子抑制剂在心脏衰老相关模型中的评价
- 批准号:
10546047 - 财政年份:2022
- 资助金额:
$ 47.05万 - 项目类别:
Discovery and Development of USP30 inhibitors as Disease-Modifying Therapy for Parkinson's disease.
USP30 抑制剂的发现和开发作为帕金森病的疾病缓解疗法。
- 批准号:
10007274 - 财政年份:2020
- 资助金额:
$ 47.05万 - 项目类别:
Parkin and differential susceptibility of dopamine neurons in Parkinson's disease
帕金森病和多巴胺神经元的不同易感性
- 批准号:
7487570 - 财政年份:2008
- 资助金额:
$ 47.05万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.05万 - 项目类别:
Research Grant